Benidipine hydrochloride has been developed as an antagonist for the
L-type calcium channel and is used as an
anti-hypertensive drug. But recent studies have reported that
benidipine exerts not only
antihypertensive actions but also anti-hypertrophic actions on cardiac muscles.
Endothelin-1 (ET-1), one of the endogenous pathological humoral factors of
cardiovascular diseases such as
hypertension and
heart failure, has a strong vasoconstrictive action and could induce
hypertension and
cardiac hypertrophy. So, it is a matter of great interest whether or not
calcium antagonists can decrease
cardiac hypertrophy induced by the pathological vasoactive substances such as ET-1. Thus, the present study was designed to elucidate the effects of
benidipine on
cardiac hypertrophy, and particularly on the interaction with ET-1, using neonatal rat cardiac myocytes (MCs) and cardiac non-myocytes (NMCs) culture systems. Cells were cultured with or without ET-1,
benidipine, and
nifedipine and the effects of
calcium antagonists on
cardiac hypertrophy were evaluated by incorporations of [3H]-
leucine and [3H]-
thymidine into MCs and/or NMCs.
Benidipine significantly decreased the ET-1-induced increase of [3H]-
leucine and [3H]-
thymidine uptake into cardiac MCs and NMCs, whereas no significant effects of
nifedipine were observed. Furthermore,
benidipine (10(-8)M) attenuated ET-1 secretions from NMCs. In summary,
benidipine at least partially decreased the
cardiac hypertrophy induced by paracrine mechanisms through its attenuation of ET-1 secretions from NMCs.
Benidipine could thus be a useful tool for preventing
cardiac hypertrophy due to
hypertension.